SUMMARY
In this edition, we received significant updates regarding the first-line chemo-free management of follicular lymphoma (FL) and Waldenström macroglobulinaemia (WM). For the treatment of relapsed/refractory (R/R) FL, new data on the use of combinations involving novel monoclonal antibodies (mAbs) and bispecific antibodies (BITEs) aim to reshape the current therapeutic landscape. These approaches challenge the widely used combination of rituximab and lenalidomide, as proposed in the AUGMENT trial, which remains a prominent option in this setting.1 Additionally, long-term follow-up data on the use of CAR-T in FL seem to support their curative potential, even in the setting of indolent lymphomas. In first-line CLL, new combinations of checkpoint inhibitors, covalent (cBTKi) and non-covalent BTK inhibitors (ncBTKi) with venetoclax and obinutuzumab show impressive efficacy and disease control. For R/R CLL, significant updates on the use of BITEs and BTK degraders highlight promising new therapeutic options, particularly addressing the unmet needs in managing double-refractory patients (cBTKi and BCL-2 inhibitors). Finally, the TRANSCEND CLL 004 trial presented impressive efficacy and safety results with the combination of CAR-T and cBTKi.
(BELG J HEMATOL 2025;16(1):7–11)
